Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just a thought does anyone know if this lqmt's material could become an ink form for future 3D printing That would be a game changer.
Gorgol lqmt is not maybe "IT IS" the tech has already been tested and proved as to what it's capable of the only thing that could screw things up is management and lqmt has put together a world class team for growth here on..if in the future they don't perform someone else will take over (IMO) for now this is up until the tech is replaced which is hard to imagine at this point however nothing is impossible (for once the mind can perceive it ..it can achieve it)
Fear will cause people to always play into the hands of MM the did that right before your eyes walk down the shares from $1 of rgbp down to .03
Play the game to WIN AND WIN BIG HOLD AND ADD Know what you own
BMSN IS a rocket ship.
Keep your eye on the ball $$ BMSN $$
Ladies and Gentlemen all systems have been checked and we've a go for take off please fastened your Bmsn seat belts and enjoy the ride.
BMSN/Regen Synopsis
BMSN currently has an outstanding share float of approximately 2.95 Billion. The market determines "fair market value" which is what a buyer will buy for and what a seller will sell for based on other factors such as company valuation, supply and demand.
Currently the Regen outstanding shares, or O/S is 51.5 Million. 1.5 Million were dispensed in private sales or distributions in consideration of a certain monetary or future monetary value.
BMSN will retain 30 Million preferred shares in which they will retain the title of majority stock holder. Those 30 million not only carry more weight in regards to voting rights, but are not common and therefore not tradeable.
Therefore, when Regen is issued a ticker from FINRA, the tradeable share float will only be 20 million shares. 51.5 - 1.5 - 30 = 20 Million.
Here is the kicker, since BMSN will retain 58% of the shares outstanding (30 Million), they will be considered a corporate asset and increase BMSN's share price all by itself.
Since BMSN is a venture capital holding company that owns Regen, the real value will be placed on Regen which is actually producing products, or at least in the testing phase to produce them.
So considering that 4 instances of private sales of 100K shares considering $100K puts Regen private share price at $1 per share. Private shares are usually given at a much lower price than public shares. For instance, most biotech IPOs have opened this year at $5-$15 per share.
Another kicker, since BMSN is the primary shareholder, for each $1 that Regen share price is it equates to $.01 for BMSN share price at the current O/S for BMSN, i.e $30 Million / 3 Billion = .01 of real company value. Meaning, if Regen opens at $1 when the public trading starts, BMSN will automatically be worth $.01, however, it doesn't mean it will trade at that price automatically.
In regards to the FDA (and this is where the real value comes in)Regen is currently awaiting FDA approval to begin human trials on Hemaxellerate to treat aplastic anemia. Since HemaXellerate will treat a rare condition, it is also eligible for orphan drug status. This will give Regen exclusive rights to the treatment for 7 years, and it is considered to be worth 100's of millions if not a billion dollars if successful.
Now, the mother of all kickers, Regen is also developing a treatment called dCellVax which is designed as a gene silencing treatment for breast cancer. Yes, I said cancer. It would be utilized as an alternative to chemotherapy and conventional cancer treatments without the side affects of nausea, weakness, and losing all of your hair.
Now, I don't know about anyone else, but a proven dCellVax treatment alone is worth billions. A treatment that fights cancer without the typical side affects will, in my opinion, make this company a legend.
I'm sure most of you have not fully grasped what kind of company that you are invested in, but I hope you see it now. If all goes as planned, spread the word. For BMSN/Regen will be the best investment any of us have ever made.
Good luck to you all, good luck to the scientists in their endeavor to treat these horrible diseases.
fda soon$$$$$$$$$$$$$$$$$$$
Know what you own... hang on for the ride folks hold tight on your bmsn shares you have and add all that you can on the dips this about to blast off!!!
Lqmt very positive things are happening from development stage to commercializing stage growth growth = rise in earnings = pps rise to new highs...
Liquidmetal reached a “significant milestone in our move to commercialize” the technology, said CEO Tom Steipp. The company settled a legal dispute over rights to the technology, and is preparing for the opening of a “manufacturing center of excellence” in October, said Steipp.
The company’s cash at the end of the quarter was $13.9 million, well up from $2.1 million at the end of last year.
Pre Market rise before tomorrow... Liquidmetal Technologies, Inc. (LQMT), the leading developer of amorphous alloys and composites, has been invited to present at the 2014 Gateway Conference being held on Thursday, September 4, 2014 at the Palace Hotel in San Francisco.
Liquidmetal management is scheduled to present at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. Management will discuss the company’s outlook for growth in 2015, being driven by their recent milestone to commercialize their technology.
Web site updated!!!!http://www.vid3g.com/
coming together for launch
Share video through SMS, Twitter, Sina weibo, and Tencent Weibo.
Did I miss something Bmsn is producing revenues? Since When?
Know what you own Using this new computational approach, we were able to take advantage of the rich data resources that exist...
and identify a number of new potential drug (IMO Dcell vax)targets for a specific subset of breast cancer patients. This is an important step down the road towards more personalized medicine," said Perou.
The one two knockout punch to cancer cure with BMSN and a new integrated approach to pinpoint the genetic "drivers" of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy. http://www.medicalnewstoday.com/releases/281544.php
Historical run of bmsn on 12/17/07 pps was at .10 6 months later pps on 6/9/08 1.29
Know what you own
This did not happen in a few weeks or even a few years this took a lot of time and here we are impatient as to a few days.... "We are pleased to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA."
Know what you own
Bmsn is so tight IMO it'll gap up once it gets moving you have to anticipate that if you'll flip it (IMO) once it takes off from whatever price point we see gap up after gap up on pps If it walks like a gap Talks like a gap Then it must be a ......(IMO)
Know What You Own and hold on to everything.
MM will try everything in the book to take your shares they can make it run so you can flip out of your shares only to chase it back or they can dump so you'll be scared and let go.
Regen BioPharma Inc. (a subsidiary of BMSN) is initiating the production of clinical-grade HemaXellerate I using the Good Manufacturing Practices (GMP)-compliant contract manufacturer Cook General Biotechnology. The initial batches will be utilized for completing preclinical experiments requested by the FDA for IND # #15376 for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia.
Since then this ruling once passed looks like a go.
Quote "III. Highlights of the Proposed Rule
The proposed rule would remove Sec. Sec. 610.11, 610.11a, and
680.3(b), the regulations that require that manufacturers of biological
products perform a specified test for general safety of biological
products. FDA is taking this action because the existing codified GST
regulations are duplicative, outmoded, or are otherwise unnecessary to
help ensure the continued safety, purity, and potency of licensed
biological products.
What's your take on This FDA ruling?
A product that meets the requirements for general safety will
comply with the criteria found in Sec. 610.11(d) of the GST
regulation, i.e., injected animals survive the test period; they do not
exhibit any response that is not specific for or expected from the
product and which may indicate a difference in quality of the product;
and they weigh no less at the end of the test period than they did at
the time of injection.
While originally a useful approach, as time has passed, the Agency
has periodically explored the utility and efficiency of this approach.
In the Federal Register of May 14, 1996 (61 FR 24227), FDA published a
final rule exempting certain biotechnology-derived and synthetic
biological products from a number of regulations applicable to
biological products, including the GST (see Sec. 601.2(c)). This
action was in response to technical advances that greatly increased the
ability of manufacturers to control the manufacture of, and to more
fully analyze the physical and biological characteristics of, many
biotechnology-derived biological products.
If You Have Cancer DCell Vax is for you....The Food and Drug Administration halted testing of the Ebola drug in healthy volunteers last month after some patients suffered inflammatory reactions at high doses. This month, however, the F.D.A. said the drug could be tested on people who were actually infected.
RNA interference, the technique used by Tekmira, is a way to turn off potentially any gene. It holds promise for treating many diseases, not just viral infections.
Such drugs typically consist of short stretches of synthesized double-stranded RNA that match part of the gene to be silenced.
$$$$$BMSN$$$$$$$ get ready hold on to your shares SUMMARY: The Food and Drug Administration (FDA) is proposing to amend
the biologics regulations by removing the general safety test (GST)
requirements for biological products. FDA is proposing this action
because the existing codified GST regulations are duplicative of
requirements that are also specified in biologics licenses, or are no
longer necessary or appropriate to help ensure the safety, purity, and
potency of licensed biological products. FDA is taking this action as
part of its retrospective review of its regulations to promote
improvement and innovation, in response to an Executive order.
On March 6, 2014, Regen submitted a protocol modification, additional details on manufacturing, and new data to the FDA regarding therapeutic effects of HemaXellerate I™ in animal models of diseases similar to aplastic anemia in humans, as well as additional safety data.
The Company reports the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested.
The proposed rule would remove the requirements contained in 21 CFR
610.11, 610.11a, and 680.3(b) from the regulations. Section 610.11
concerns a GST for the detection of extraneous toxic contaminants in
biological products intended for administration to humans. Section
610.11a concerns the GST regulations for inactivated influenza vaccine.
Section 680.3(b) concerns GST regulations for allergenic products.
Removal of these regulations would not remove GST requirements
specified in individual BLAs, however. A biological product
manufacturer would continue to be required to follow the GST
requirements specified in its BLA unless the BLA were revised to
eliminate or modify the test through a supplement in accordance with 21
CFR 601.12(c). FDA would review proposed changes to a manufacturer's
approved biologics license on a case-by-case basis so that we could
ensure that any such action is appropriate.
BMSN was approved according to this
Not Sure of this but it seems as If the FDA does not need to test for BMSN's proposed vaccine.
The proposed rule would remove the requirements contained in 21 CFR
610.11, 610.11a, and 680.3(b) from the regulations. Section 610.11
concerns a GST for the detection of extraneous toxic contaminants in
biological products intended for administration to humans. Section
610.11a concerns the GST regulations for inactivated influenza vaccine.
Section 680.3(b) concerns GST regulations for allergenic products.
Removal of these regulations would not remove GST requirements
specified in individual BLAs, however. A biological product
manufacturer would continue to be required to follow the GST
requirements specified in its BLA unless the BLA were revised to
eliminate or modify the test through a supplement in accordance with 21
CFR 601.12(c). FDA would review proposed changes to a manufacturer's
approved biologics license on a case-by-case basis so that we could
ensure that any such action is appropriate.
Am I understanding this new FDA policy as to the license of
The proposed rule would eliminate the codified GST \1\ regulations
for biological products. FDA is proposing this action because the
existing codified GST regulations are duplicative of requirements that
are also specified in biologics license applications (BLAs) or are no
longer necessary or appropriate to help ensure the safety, purity, and
potency of licensed biological products. FDA is taking this action as
part of its retrospective review of its regulations to promote
improvement and innovation, in response to Executive Order (E.O.) 13563
of January 18, 2011.
The dCellVax therapeutic product uses patents that Regen BioPharma has in-licensed from Dr. Wei-Ping Min coupled with patents in-licensed from Benitec BioPharma.
Does anyone know if wlan is into the early warning system for the earthquakes? sure seems to all over the news.
Looking like a power hour run is setting up 20 off the 50 ma
Tom this is your next move for xsnx http://www.mercurynews.com/business/ci_25777563/q-sunpower-ceo-tom-werner-solars-next-big
Tom this is your next move for xsnx http://www.mercurynews.com/business/ci_25777563/q-sunpower-ceo-tom-werner-solars-next-big
Xsnx is moving in the right direction soon storage solution will be the package
As we move closer to FDA approval the payoff would be insignificant that's what R&D is all about if you invested in bmsn one should understand this fact they'll have a burn rate for quite some time but now the payoff is here everyone wants to take your shares away from you and they will only if you let them
Benitec Biopharma Limited – 2014 Annual Report
Page 9
Licensed Programs
In addition to the Company’s in-house development programs, Benitec has licensed its ddRNAi technology to
four biotech companies. As each of these companies advances their clinical development their success further
validates ddRNAi.
? Breast cancer – Benitec has granted a license to Regen Biopharma for the development of a ddRNAibased
therapy called dCellVax. Regen recently announced the successful silencing of the IDO gene in
dendritic cells, an approach that in animal models has demonstrated the ability to induce regression
of breast cancer.
bmsn know what you own
Strategic Advantage
Benitec’s ddRNAi technology is a form of RNA interference (RNAi) that can ‘silence’ or shut down diseasecausing
genes. Recently there has been an increasing awareness of the value of gene silencing and RNAi as a
therapeutic modality; Companies operating in this segment – such as Alnylam, Arrowhead, Dicerna, Tekmira,
Bluebird Bio and Isis – have seen significant increases in their valuation. In particular, Alnylam has grown its
Benitec Biopharma Limited – 2014 Annual Report
Page 7
company’s market capitalisation from around $1 Billion to over $4 Billion over the last two years. Benitec’s
ddRNAi technology has a number of differential advantages over RNAi: the most important is its ability to
silence a disease-causing gene for long periods with a single administration, whereas conventional RNAi
requires continuous administration.
Big pharma is demonstrating a renewed interest in RNAi and gene therapy. Benitec’s ddRNAi technology offers
an optimised combination of these approaches, and the TT-034 clinical trial, if successful, will provide
validation of the technology for treating a wide range of diseases.
support may be at .0115 if it holds if not it's south to 50 ma if that don't hold it the bears will be all over sltd
Rule #1 Keep emotions in check it'll make you lose every time.
state the facts as to why you feel bmsn will go to triple zero.
Share
Tools
Comment
Print
Contact Author
Reprint
Courtesy of Daniel Schwen
CHICAGO--When the curtain goes up at ASCO here tomorrow, you can bet that one subject will dominate the entire conference: immuno-oncology. But the number of prominent players on the immunopalooza stage this year is likely to grow as analysts fix on the swelling lineup of studies that are attracting global attention from cancer patients and physicians.
In the traditional lead-up to ASCO, Bloomberg today assembled a comprehensive look at the pipeline for immunotherapies, and it should leave no doubt that Bristol-Myers Squibb ($BMY) is gambling the lion's share of the estimated $1.3 billion committed to fund 78 currently known trials which will enroll 19,000 cancer patients.
Bristol-Myers, Naomi Kresge and Robert Langreth report, is devoting an estimated $649 million to its immuno-oncology work, which is primarily devoted to getting nivolumab through the clinic and into the market. Merck ($MRK), which is furiously at work on MK-3475 as many of the rest of its projects struggle, at one point recently described its immuno-oncology program as a pipeline unto itself. But the pharma giant is actually a distant second at this stage of the race, at least in terms of spending, with an estimated commitment of $327 million. Then Roche ($RHHBY) and AstraZeneca ($AZN) bring up the rear, with programs costing an estimated $189 million and $145 million, respectively.
Webinar: The Basics of Biotech 101, 201 & 301
Individual Session: $129, Full Series: $299
This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Register Now!
Sign up for our FREE newsletter for more news like this sent to your inbox!
It was AstraZeneca's budding prospects with its immuno-oncology program for the PD-L1 therapy MEDI4736 that helped it avoid the clutches of Pfizer ($PFE), first by demonstrating that its pipeline had real potential and then by figuring in on Pascal Soriot's claim that a Pfizer takeover would disrupt their R&D efforts, potentially leaving patients to die.
Roche hasn't enjoyed as much attention for its PD-L1 program for MPDL3280A, but new data from a small study on bladder cancer looked promising and its Genentech unit is looking to make a splash in Chicago.
Rarely a week goes by without a few new immuno-oncology research deals to report, as even a casual reader of FierceBiotech will likely note. The reason is simple: Investigators believe they have figured out a way to dismantle the mechanism used by cancer cells to stay hidden from the immune system. It's a broadly applicable approach which is likely to work in combination with a number of therapies. And after Citigroup last year put a $35 billion figure on the market potential for these drugs, the oft-cited megablockbuster number helps explain why these companies are so interested in being among the first to the market.
"I have never seen this much enthusiasm collectively for a class of drugs before," Asthika Goonewardene, a London-based analyst at Bloomberg Industries, tells the reporters. "This is essentially what we call a land grab. There's opportunity, and everybody is going out to find what that opportunity is."
The gold rush is being driven by projections that these drugs can come with a low six-figure price tag. But after Sovaldi helped spur a revolt among payers astonished by the price tag, getting a megablockbuster payback on these programs could be easier said than done.
Cancer vaccines were once the darlings of the R&D field for immunotherapies, but as Emily Mullin reports in FierceVaccines, a string of failures has seriously dimmed the prospects for the one-time leaders in the field. Still, some new biotechs are coming along. And as I reported in a separate story today, big players like J&J are looking to find some new ways to better apply some old, and failed, technologies.